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Abstract
Background: Onset of canine transitional cell carcinoma (TCC) and prostatic carcinoma (PCA) is usually insidious with
dogs presenting at an advanced stage of the disease. A biomarker that can facilitate early detection of TCC/PCA and
improve patient survival would be useful. S100A8/A9 (calgranulin A/B or calprotectin) and S100A12 (calgranulin C) are
expressed by cells of the innate immune system and are associated with several inflammatory disorders. S100A8/A9 is
also expressed by epithelial cells after malignant transformation and is involved in the regulation of cell proliferation
and metastasis. S100A8/A9 is up-regulated in human PCA and TCC, whereas the results for S100A12 have been
ambiguous. Also, the urine S100A8/A9-to-S100A12 ratio (uCalR) may have potential as a marker for canine TCC/PCA.
Aim of the study was to evaluate the diagnostic accuracy of the urinary S100/calgranulins to detect TCC/PCA in dogs
by using data and urine samples from 164 dogs with TCC/PCA, non-neoplastic urinary tract disease, other neoplasms,
or urinary tract infections, and 75 healthy controls (nested case-control study). Urine S100A8/A9 and S100A12
(measured by species-specific radioimmunoassays and normalized against urine specific gravity [S100A8/A9USG;
S100A12USG], urine creatinine concentration, and urine protein concentration and the uCalR were compared among
the groups of dogs.
Results: S100A8/A9USG had the highest sensitivity (96%) and specificity (66%) to detect TCC/PCA, with specificity
reaching 75% after excluding dogs with a urinary tract infection. The uCalR best distinguished dogs with TCC/
PCA from dogs with a urinary tract infection (sensitivity: 91%, specificity: 60%). Using a S100A8/A9USG ≥ 109.9 to
screen dogs ≥6 years of age for TCC/PCA yielded a negative predictive value of 100%.
Conclusions: S100A8/A9USG and uCalR may have utility for diagnosing TCC/PCA in dogs, and S100A8/A9USG may
be a good screening test for canine TCC/PCA.
Keywords: Biomarker, Calprotectin, Diagnostic accuracy, S100A8/A9, S100A12, Transitional cell carcinoma
Background
Transitional cell carcinoma (TCC) is the most common
naturally occurring lower urinary tract malignancy in
dogs affecting a number of canine patients [1–3]. Several
predisposing factors (including the use of certain drugs,
chemicals, or preventive medications, breed, gender, and
diet) have been evaluated (reviewed by Fulkerson et al.
[3]). Despite many advances in the management of dogs
with TCC or prostatic carcinoma (PCA), early detection
of these neoplasms is rare, and their onset is usually in-
sidious with dogs presenting at an advanced stage of
the disease (20–40% with metastasis) [1–4]. Thus, as
with any cancer, a biomarker that can facilitate early
detection of TCC/PCA (i.e., cancer screening) and im-
prove patient survival would be a useful tool in clinical
practice.
Urinary cytology as a test for TCC/PCA has been
demonstrated to have a low sensitivity and specificity
[3, 5]. The veterinary bladder tumor antigen (V-BTA)
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test has been evaluated as a non-invasive screening tool
for TCC in dogs and is currently the biomarker with the
best diagnostic accuracy for non-invasive TCC diagnosis,
but this test was shown to have a high false-positive rate
(12–65%) [6–9]. Concentrations of urinary basic fibroblast
growth factor was also increased in dogs with bladder can-
cer and to some extent discriminated dogs with TCC from
dogs with a urinary tract infection (UTI) [10], but sensitiv-
ity and specificity of urinary basic fibroblast growth factor
have not been reported in a larger population of dogs. A
recent urine metabolomics study identified a metabolite
signature that could discriminate dogs with TCC from
healthy control dogs with a sensitivity of 86% and a speci-
ficity of 78% [11], and a mass spectrometry analysis of ca-
nine urine samples identified a multiplex biomarker
model predicting the presence of TCC with 90% diagnos-
tic accuracy [12]. However, the utility of these models as
either a screening tool or a diagnostic test for canine TCC
has not been evaluated to date.
S100A8/A9 (calgranulin A/B) and S100A12 (calgranu-
lin C) are members of the S100/calgranulin family of
Ca2+-binding proteins, and both members are expressed
by cells of the innate immune response [13]. Aside from
its association with several inflammatory diseases [13, 14],
the S100A8/A9 protein complex (also referred to as cal-
protectin) has been shown to be expressed by epithelial
cells after malignant transformation [15–18] and to be in-
volved in the regulation of cell proliferation [19] and me-
tastasis [20, 21]. In humans, both S100A9 and S100A8
were found to be up-regulated in PCA and TCC [22–30],
whereas studies on the expression of S100A12 in TCC/
PCA have yielded ambiguous results [31, 32]. However,
S100A12 has not been investigated extensively in cancer
patients.
Similar to human urothelial carcinoma, the S100A8/A9
gene has been shown to harbour an increased frequency
of copy number gains in canine urothelial carcinoma [33],
and pilot data by our group suggested that the urinary
concentration of S100/calgranulins, particularly the
S100A8/A9-to-S100A12 ratio (uCalR), may have potential
as a diagnostic biomarker for TCC/PCA in dogs [34].
Thus, further evaluation of the urinary S100/calgranulins
and uCalR in dogs is needed to determine their specificity
for the diagnosis of TCC/PCA. This retrospective case-
control study investigated urine S100A8/A9 and S100A12
concentrations as well as the uCalR in dogs with TCC/
PCA (treated or treatment-naïve), dogs with other diseases
of the urinary tract, dogs with neoplastic diseases not
involving the urinary tract, and healthy control dogs.
We hypothesized (1) that the concentration of S100/
calgranulins in urine specimens is a useful screening
test for TCC/PCA and (2) that the uCalR can distin-
guish dogs with TCC/PCA and UTI with high diagnostic
accuracy.
Methods
Sampling population
A nested case-control study design was used. Urine sam-
ples from dogs with TCC/PCA that were treatment-naïve
(n = 22) or receiving specific anticancer treatment at the
time of sampling (n = 40), dogs with non-neoplastic dis-
eases of the urinary tract (n = 22), dogs with other neo-
plasms (n = 35), dogs with a urinary tract infection (UTI;
n = 45), and a group of healthy control dogs (n = 75) were
used. The study design is summarized in the flow chart
(Fig. 1). Cases were recruited at the Veterinary Medical
Teaching Hospitals (VMTH) at Texas A&M University
(n = 99), Michigan State University (n = 62) as part of an-
other study [9], and three other North American univer-
sities (n = 40) as well as from seven Oncology referral
practices located in five different US states (n = 38).
Samples from some of the dogs (9 dogs with TCC/PCA,
9 dogs with a UTI, and 38 healthy dogs) had also been
included in the assay validation study [34].
Complete patient information was extracted from
the electronic medical records (for all VMTH cases)
or a study questionnaire that had to be completed
by the owner and/or the attending veterinary on-
cologist prior to patient enrolment (for all referral
practice cases).
Sample collection and analyses
Urine samples were obtained by cystocentesis, urethral
catheterization, or free-catch, and were prepared for ana-
lysis of S100A8/A9 and S100A12 as previously described
[34]. Briefly, debris was separated from samples by cen-
trifugation for three minutes at 1000 × g, and the su-
pernatants were placed into cryovials and stored frozen
at −80 °C until analyses. Urine samples were then thawed
and diluted 1:2 in 0.05 M sodium phosphate, 0.02% so-
dium azide, and 0.5% bovine serum albumin (pH 7.5) [34].
Urine S100A8/A9 and S100A12 were measured in all
samples using established and validated species-
specific in-house radioimmunoassays [34]. Urine con-
centrations of S100A8/A9 and S100A12 were normal-
ized against urine specific gravity1 (S100A8/A9USG and
S100A12USG), urine creatinine concentration
2 (S100A8/
A9Cre and S100A12Cre), and urine protein concentration
3
(S100A8/A9Prot and S100A12Prot) [34]. In addition, the
S100A8/A9-to-S100A12 ratio (uCalR) was calculated for
each sample [34].
Data analyses
Commercial statistical software packages4,5 were used for
all statistical analyses. Data were tested for the assumptions
of normality and equality of variances using a Shapiro-Wilk
and a Brown-Forsythe test, respectively. All parame-
ters (S100A8/A9USG, S100A8/A9Cre, S100A8/A9Prot,
S100A12USG, S100A12Cre, S100A12Prot, and uCalR) were
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tested among the six different groups of dogs using
non-parametric multiple- (Kruskal-Wallis test followed
by a Dunn’s test for multiple comparisons) or two-
group (Mann-Whitney U test) comparisons. Summary
statistics are reported as medians and interquartile ranges
(IQR).
Receiver operating characteristic (ROC) curves were
constructed to determine the sensitivities and specific-
ities of normalized urinary S100A8/A9, S100A12, and
the uCalR to distinguish dogs with TCC/PCA from the
other groups of dogs; the Youden index was used to es-
tablish the optimum cut-off values. Positive (PPV) and
negative predictive values (NPV) were calculated for the
best-performing markers; the prior probability for a
diagnosis of TCC/PCA in middle aged to older dogs
(defined as ≥6 years of age) was estimated at 0.7% [2],
and in dogs older than 6 years after exclusion of a UTI
and those with clinical signs of lower urinary tract disease
was estimated at 1% and 20%, respectively [8]. Significance
was set at P < 0.05.
Results
Study population
Treatment-naïve TCC/PCA dogs
Breeds included Beagle (n = 3), Labrador Retriever
(n = 3), Australian Cattle dog (n = 2), Scottish Terrier
(n = 2), Shetland Sheepdog (n = 2), Australian Shepherd
dog, Boston Terrier, Chow, Fox Terrier, Lhasa Apso (each
n = 1), and mixed breed (n = 5). The most common tumor
location was the urinary bladder (n = 15), followed by the
urethra (n = 7), and the prostate (n = 5). The diagnosis
was confirmed by histopathologic evaluation of a tissue
biopsy (n = 7) or cytology (n = 15). A urine culture was
performed in 12 dogs, 5 (42%) of which were positive
for bacterial growth and the majority (80%) of positive
samples were growing a single organism (E. coli,
Fig. 1 Study flow chart summarizing the group distribution of the 239 dogs included into the study. The two different parts of the study are marked by
the grey shaded areas: (i) evaluation of the urinary S100/calgranulins in dogs with a defined disease state; and (ii) evaluation of the diagnostic accuracy of
the urinary S100/calgranulins for the diagnosis of transitional cell carcinoma (TCC)/prostatic carcinoma (PCA) in dogs ≥6 years of age (n = 141). #e.g., lack
of a definitive diagnosis, not possible to categorize in one group (e.g., concurrent non-urinary tract malignancy and urinary tract infection), abnormal
urinalysis results in healthy controls, or Leptospirosis suspect (analysis of urine considered as a possible public health concern)
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Enterococcus sp., Pseudomonas aeruginosa, or Streptococ-
cus equisimilis).
TCC/PCA dogs under treatment
Breeds included Beagle (n = 5), Shetland Sheepdog
(n = 4), West Highland White Terrier (n = 4), Scottish
Terrier (n = 2), American Spitz, Bichon Frise, English
Springer Spaniel, Jack Russell Terrier, Labrador Retriever,
Maltese, Miniature Pinscher, Miniature Schnauzer, Papil-
lion, Poodle, Rat Terrier, Schipperke (each n = 1), and
mixed breed (n = 13). Most common tumor site was the
urinary bladder (n = 33), followed by the prostate (n = 7),
and the urethra (n = 6). Treatment at the time of urine
sample collection included non-steroidal anti-inflammatory
drugs (NSAID; piroxicam: n = 30; carprofen: n = 4;
firocoxib: n = 2; deracoxib: n = 1), chemotherapy
(mitoxantrone: n = 5; cyclophosphamide: n = 1), a
tyrosine kinase inhibitor (toceranib phosphate: n = 3),
and/or surgical excision (n = 2). The diagnosis had
been previously confirmed by histopathology or cytology.
A urine culture was performed in 7 dogs, 3 (43%) of which
were positive for bacterial growth and a single organism
(E. coli, Aerococcus sp., Mycoplasma canis) being isolated
in the majority (80%) of the dogs that had a positive urine
culture.
Dogs with UTI
Breeds included Beagle (n = 3), Boston Terrier (n = 3),
Labrador Retriever (n = 3), Pug (n = 3), Standard
Schnauzer (n = 3), Bichon Frise (n = 2), Brittany Spaniel
(n = 2), Dachshund (n = 2), Golden Retriever (n = 2),
Australian Cattle dog, Boxer, Cocker Spaniel, English
Bulldog, Fox Terrier, French Bulldog, Great Dane, Husky,
Jack Russell Terrier, Lhasa Apso, Miniature Poodle,
Miniature Schnauzer, Pembroke Welsh Corgi, Rat Terrier,
Rottweiler, Shih Tzu, Swiss Mountain dog (each n = 1),
and mixed breed (n = 5). Urine culture was positive in
44/45 (98%) dogs, and marked bacteriuria but a nega-
tive culture was seen in one dog. The isolated bacterial
strains were documented in 38 dogs, 6 (16%) of which
had a polymicrobial UTI. The most common isolate
was E. coli (n = 21), followed by Enterococcus sp.
(n = 5), Klebsiella (n = 3), Proteus mirabilis (n = 6),
Staphylococcus pseudintermedius (n = 2), Streptococcus
canis (n = 2), Actinobacillus sp., Bacillus sp., Enterobac-
ter sp., Pasteurella sp., Pseudomonas aeruginosa (each
n = 1). A recurrent UTI was seen in one dog and a re-
sistant UTI in two dogs. One dog had concurrent bilat-
eral ureteral ectopy and one dog had urolithiasis.
Dogs with non-neoplastic urinary tract diseases
Breeds included Miniature Schnauzer (n = 3), Beagle
(n = 2), Maltese (n = 2), Australian Shepherd, Bichon
Frise, Bloodhound, Chihuahua, Dalmatian, Golden Retriever,
Labrador Retriever, Miniature Poodle, Standard Schnauzer,
Soft Coated Wheaten Terrier, Shih Tzu, West Highland
White Terrier, Yorkshire Terrier (each n = 1), and mixed
breed (n = 2). Diseases included urolithiasis (n = 11),
International Renal Interest Society (IRIS) stage I-IV
chronic kidney disease (n = 7), detrusor sphincter dys-
synergia, polypoid cystitis, urethral stricture, or urethral
sphincter mechanism incompetence (each n = 1).
Dogs with non-urinary tract neoplasia
Breeds included Beagle (n = 6), Labrador Retriever
(n = 5), Shetland Sheepdog (n = 3), West Highland
White Terrier (n = 3), Golden Retriever (n = 2), Scottish
Terrier (n = 2), Basset Hound, Bearded Collie, Boxer,
Brittany Spaniel, Cockapoo, German Shorthaired Pointer,
Greater Swiss Mountain dog, Rottweiler (each n = 1), and
mixed breed (n = 6). Neoplastic diseases were: lymphoma
(n = 5), mast cell tumor (n = 5), hepatocellular carcinoma
(n = 4), appendicular osteosarcoma (n = 3), undefined
adrenal masses (n = 2), undefined splenic masses with
hemoabdomen (n = 2), thymoma (n = 2), adrenal car-
cinoma, hemangiosarcoma, hepatic carcinoma, oral soft
tissue sarcoma, oral squamous cell carcinoma, perianal
adenoma, plasma cell tumor, pulmonary carcinoma, renal
adenocarcinoma, undefined intracranial neoplasia, un-
defined mandibular neoplasia, and undefined mesenchy-
mal neoplasia (each n = 1). Oncologic therapy at the time
or prior to urine sample collection for the study included
surgery (n = 12), chemotherapy (n = 8), and/or radiation
therapy (n = 2).
Healthy control dogs
Breeds included West Highland White Terrier (n = 7),
Beagle (n = 4), Labrador Retriever (n = 4), Dachshund
(n = 3), Scottish Terrier (n = 3), Shetland Sheepdog
(n = 3), American Pitbull Terrier (n = 2), Giant Schnauzer
(n = 2), Miniature Schnauzer (n = 2), Weimaraner (n = 2),
Yorkshire Terrier (n = 2), Australian Shepherd, Basset
Hound, Bichon Frise, Border Collie, Boston Terrier, Boxer,
Chihuahua, Chinese Shar Pei, English Springer Spaniel,
French Bulldog, Golden Retriever, Great Dane, Neopolitan
Mastiff, Portuguese Water dog, Saint Bernard, Standard
Poodle, White Shepherd dog (each n = 1), and mixed
breed (n = 17); breed was not documented in 7 dogs.
Urinalysis was unremarkable in 64 dogs and was not per-
formed on the same urinalysis in 11 dogs (these dogs were
determined to be healthy based on previous diagnostics).
Age-related conditions (e.g., degenerative joint disease)
not reported to affect the urinary tract were not consid-
ered as an exclusion criterion.
Among group comparisons
Patient characteristics, urine S100A8/A9 and S100A12
concentrations, and the uCalR are summarized in Table 1.
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S100A8/A9USG (Fig. 2) and S100A8/A9Cre were numeric-
ally higher in dogs with untreated TCC/PCA than in dogs
with TCC/PCA under treatment, but both differences did
not reach significance (P = 0.2587 and 0.3715, respect-
ively). No differences in S100A8/A9USG (Fig. 2) and
S100A8/A9Cre were seen between treatment-naïve TCC/
PCA dogs and those with a UTI (P = 0.1763 and 1.0000,
respectively). Compared to treatment-naïve TCC/PCA
dogs, urinary S100A12 concentrations were also lower
in TCC/PCA dogs undergoing treatment, but the differ-
ence was only significant for S100A12Cre (P = 0.0416;
P = 0.0664 for S100A12USG), whereas dogs with a UTI
had numerically higher (but not significant) S100A12USG
and S100A12Cre (both P = 1.0000).
The uCalR did not differ between newly diagnosed
TCC/PCA dogs and those undergoing treatment
(P = 1.0000), but the uCalR was significantly lower in
dogs diagnosed with a UTI compared to all other dis-
ease groups of dogs: treatment-naïve TCC/PCA dogs
(P = 0.0014) (Fig. 3), TCC/PCA dogs undergoing treat-
ment (P < 0.0001), non-neoplastic urinary tract diseases
(P = 0.0049), and neoplastic disease not involving the
urinary tract (P = 0.0364).
S100A8/A9Prot and S100A12Prot were significantly
higher in dogs with TCC/PCA than those with non-
neoplastic urinary tract diseases (P = 0.0079 and 0.0485,
respectively) or other neoplasms (P < 0.0001 and 0.0056,
respectively) but were comparable to those in dogs with
a UTI (both P = 1.0000) and healthy controls (both
P = 1.0000).
Comparing urinary canine S100/calgranulin concen-
trations amongst the same groups of dogs after exclusion
of all dogs <6 years of age yielded similar results, with
the exception that the difference did not reach signifi-
cance for S100A12USG in treatment-naïve TCC/PCA
dogs compared to dogs with non-neoplastic urinary tract
disease (P = 0.0574) and healthy control dogs (P = 0.0566),
for S100A12Cre between treatment-naïve TCC/PCA
dogs and those dogs with TCC/PCA under treatment
(P= 0.1526), and for S100A12Prot between treatment-naïve
TCC/PCA dogs and dogs with non-neoplastic urinary
tract disease (P = 0.2245).
Within group comparisons
In patients with TCC/PCA, S100A8/A9USG, S100A8/A9Cre,
S100A8/A9Prot, S100A12USG, S100A12Cre, S100A12Prot, and
uCalR did not differ between dogs with a single tumor site
(bladder, urethra, or prostate; n = 53) and dogs with more
than one of those sites affected (n = 9; all P > 0.05). This
finding was no different in treatment-naïve TCC/PCA dogs
(all P > 0.05) and those dogs receiving antitumor therapy at
the time of sample collection (all P > 0.05).
S100A8/A9Prot and S100A12Prot were significantly
higher in treatment-naïve TCC/PCA dogs with a positive
urine culture (n = 5; median [IQR]: 604.8 [392.9–10,353.6]
and 39.8 [13.4–870.0], respectively) than dogs without a
concurrent UTI (n = 7; median [IQR]: 44.5 [32.4–181.2]
and 2.5 [1.1–6.1], respectively; both P = 0.0230),
whereas no differences in S100A8/A9USG, S100A8/A9Cre,
Fig. 2 Urinary concentrations of S100A8/A9 normalized against urine specific gravity (S100A8/A9USG) were significantly higher in newly diagnosed
TCC/PCA dogs compared to dogs with non-neoplastic urinary tract (UT) diseases (P = 0.0088), dogs with neoplastic diseases not involving the urinary
tract (P < 0.0001), and healthy control dogs (P < 0.0001); but did not differ from S100A8/A9USG measured in dogs with TCC/PCA undergoing cancer
therapy (P = 0.2587) or dogs with a bacterial urinary tract infection (UTI; P = 0.1763). Boxes: interquartile range (IQR); vertical lines within boxes: medians;
whiskers: determined by the outermost data points or values computed as (25th quartile – 1.5 × IQR) or (75th quartile +1.5 × IQR); dashed line: optimum
cut-off concentration (≥109.9) to distinguish dogs with TCC/PCA from those of other groups; **significant difference at P < 0.01; ***significant difference
at P < 0.001
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S100A12USG, S100A12Cre, or uCalR were seen between
both groups of dogs (all P > 0.05).
S100A8/A9USG, S100A8/A9Cre, S100A8/A9Prot,
S100A12USG, S100A12Cre, S100A12Prot, and uCalR did
not differ among the three different primary tumor
sites in newly diagnosed TCC/PCA dogs (all global
P > 0.05), whereas S100A8/A9USG, S100A12USG,
S100A12Cre, and S100A12Prot were significantly lower with
primary involvement of the urinary bladder (n = 31;
median [IQR]: 161.4 [67.3–361.5], 3.3 [2.3–13.5], 6.6
[3.6–32.9], and 2.0 [0.7–9.5], respectively) than the
prostate (n = 7; median [IQR]: 1849.6 [563.1–5641.2],
239.6 [10.3–1274.4], 254.0 [18.9–2196.2], and 58.1
[9.2–119.0], respectively) in dogs undergoing treatment
(P = 0.0274, 0.0020, 0.0128, and 0.0165, respectively).
Also, S100A8/A9USG, S100A8/A9Cre, S100A8/A9Prot,
S100A12USG, S100A12Cre, S100A12Prot, and uCalR did
not differ between dogs treated with a single agent
(n = 30) compared to combination protocols (n = 10;
all P > 0.05) nor those treated with an NSAID (n = 37)
compared to dogs not receiving an NSAID (n = 3; all
P > 0.05).
In patients diagnosed with a UTI, S100A8/A9USG,
S100A8/A9Cre, S100A8/A9Prot, S100A12USG, S100A12Cre,
S100A12Prot, and uCalR did not differ in dogs with a single
bacterial isolate (n = 43) from those with a polymicrobial
UTI (n = 7; all P > 0.05); and there were no differences
seen in dogs where only Enterococcus sp. (n = 5) and/or
other isolates (n = 45) were cultured from urine samples
(all P > 0.05).
Diagnostic accuracy
The area under the ROC curve (AUROC), optimum
cut-off concentrations (and cut-off concentrations for
at least a 90% sensitivity and a 90% specificity, respect-
ively), sensitivities, and specificities are summarized in
Table 2.
Using a uCalR of ≥9.3 or a S100A8/A9USG of ≥109.9
to screen middle-aged to older dogs (≥ 6 years of age)
for TCC/PCA (0.7% estimated prevalence of TCC/PCA)
yielded an NPV of 100% (1.000 for both) and a PPV be-
tween 1 and 2% (0.011 and 0.019, respectively). If a UTI
has been excluded in the same population of dogs
(estimated prevalence of TCC/PCA: 1%), a S100A8/
A9USG ≥ 109.9 resulted in a NPV of ~100% (1.000)
and a PPV of ~4% (0.038). In dogs ≥6 years of age, a
uCalR of ≥5.2 [or ≥9.1] or a S100A8/A9USG of ≥96.3
differentiated patients with TCC/PCA from those with
non-neoplastic causes of similar presenting signs (esti-
mated prevalence of TCC/PCA in this population:
20%) with a NPV of 96–100% (1.000 [0.956] and
0.975, respectively) and a PPV of 29–31% (0.294
[0.308] and 0.301, respectively).
Use of a uCalR of ≥9.1 combined with a S100A8/
A9USG of ≥109.9 to screen middle-aged to older dogs (≥
6 years of age) for TCC/PCA (estimated prevalence:
0.7%) yielded a sensitivity of 86% (95% CI: 67–95%) and
a specificity of 80% (95% CI: 72–87%; OR: 25.6, 95% CI:
7.3–88.5) (Fig. 4), with a NPV of ~100% (0.999; 95% Cl:
0.997–1.000) and a PPV of 3% (0.030; 95% CI: 0.020–
0.044).
Fig. 3 Urinary S100A8/A9-to-S100A12 ratios (uCalR) were significantly lower in dogs diagnosed with a urinary tract infection (UTI) compared to
treatment-naïve TCC/PCA dogs (P = 0.0014), but did not differ between newly diagnosed TCC/PCA dogs and all other disease groups (all P = 1.0000)
or healthy control dogs (P = 0.3030). Boxes: interquartile range (IQR); vertical lines within boxes: medians; whiskers: determined by the outermost data
points or values computed as (25th quartile – 1.5 × IQR) or (75th quartile +1.5 × IQR); dashed line: optimum cut-off concentration (≥9.1) to distinguish
dogs with TCC/PCA from dogs with a UTI; **significant difference at P < 0.01
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Discussion
This study evaluated the diagnostic utility of measuring
urine concentrations of S100A8/A9 and S100A12 as well
as the uCalR in dogs with TCC/PCA (treatment-naïve or
undergoing antineoplastic therapy). Measurement of these
biomarkers in urine specimens has the advantage of yield-
ing information from the urinary tract. However, the results
may be skewed by prerenal factors (e.g., increased amino
acid turnover with neoplastic diseases causing glomerular
Table 2 Sensitivities and specificities at the optimal cut-off
values (and cut-offs for resulting in a sensitivity and specificity of
at least 90% each), and area under the receiver operating
characteristic curve (AUROC) for urinary S100/calgranulins and
the S100A8/A9-to-S100A12 ratio (uCalR) to distinguish treatment-
naïve dogs with transitional cell carcinoma (TCC)/prostatic
carcinoma (PCA) from other groups of dogs (all dogs ≥6 years
of age [n = 141])
Parameter AUROC† Cut-off Sensitivity Specificity
Treatment-naïve TCC/PCA (n = 22) vs. UTI (n = 35)
S100A8/A9USG 0.671 ≥96.3 96% 43%
≥8180.7 32% 94%
S100A8/A9Cre 0.612 ≥160.0 96% 35%
S100A12USG 0.516 ≤3.2 91% 29%
S100A12Cre 0.521 ≤117.9 68% 62%
uCalR 0.751 ≥9.1 91% 60%
≥5.2 100% 49%
≥72.2 18% 94%
Treatment-naïve TCC/PCA vs. other diseases causing lower urinary
tract signs (n = 45)
S100A8/A9USG 0.684 ≥96.3 96% 44%
≥8230.7 32% 96%
S100A8/A9Cre 0.631 ≥167.8 96% 39%
S100A12USG 0.548 ≥7.0 82% 42%
S100A12Cre 0.517 ≥8.7 96% 34%
uCalR 0.698 ≥5.2 100% 40%
≥9.1 91% 49%
≥72.2 18% 96%
Treatment-naïve TCC/PCA vs. other disease groups (n = 86)a
S100A8/A9USG 0.807 ≥109.9 96% 64%
≥2274.8 36% 92%
S100A8/A9Cre 0.763 ≥188.9 96% 55%
≥8603.1 27% 91%
S100A12USG 0.712 ≥4.0 91% 57%
≥776.1 23% 93%
S100A12Cre 0.697 ≥8.7 96% 78%
≥2538.9 18% 95%
uCalR 0.664 ≥9.3 91% 42%
≥83.4 18% 96%
Treatment-naïve TCC/PCA vs. all other groups (n = 119)a
S100A8/A9USG 0.824 ≥109.9 96% 66%
≥2274.8 36% 93%
S100A8/A9Cre 0.787 ≥188.9 96% 59%
≥5783.2 36% 92%
S100A12USG 0.740 ≥7.0 82% 66%
≥221.0 27% 90%
S100A12Cre 0.722 ≥8.7 96% 57%
≥833.8 23% 90%
Table 2 Sensitivities and specificities at the optimal cut-off
values (and cut-offs for resulting in a sensitivity and specificity of
at least 90% each), and area under the receiver operating
characteristic curve (AUROC) for urinary S100/calgranulins and
the S100A8/A9-to-S100A12 ratio (uCalR) to distinguish treatment-
naïve dogs with transitional cell carcinoma (TCC)/prostatic
carcinoma (PCA) from other groups of dogs (all dogs ≥6 years
of age [n = 141]) (Continued)
uCalR 0.657 ≥9.3 91% 41%
≥83.4 18% 96%
Treatment-naïve TCC/PCA vs. all other groups, excl. Urinary tract
infections (n = 84)
S100A8/A9USG 0.896 ≥109.9 96% 75%
≥374.9 59% 95%
S100A8/A9Cre 0.875 ≥188.9 96% 70%
≥792.7 55% 91%
S100A12USG 0.850 ≥8.6 77% 86%
≥4.0 91% 71%
S100A12Cre 0.838 ≥10.7 91% 76%
≥92.3 32% 91%
uCalR 0.612 ≥9.3 91% 33%
aexcluding TCC/PCA dogs undergoing anticancer therapy
†values in boldface are significant at P < 0.05
Fig. 4 Four-way Venn diagram demonstrating the separation between
dogs with TCC/PCA (treatment-naïve) and all other groups of
dogs ≥6 years of age by use of a uCalR ≥9.1 combined with
a S100A8/A9USG ≥ 109.9
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hyperfiltration [35]), renal diseases (e.g., chronic kidney
disease), and/or other diseases of the lower urinary tract
(e.g., bacterial cystitis or urolithiasis). Thus, dogs with
other non-neoplastic diseases of the urinary tract and dogs
with neoplastic conditions not involving the urinary tract
were included as disease control groups of dogs.
Diagnostic accuracy of the urinary canine S100/
calgranulins was evaluated in dogs ≥6 years of age to
mimic the situation of using these biomarkers in the
clinical setting to screen for or diagnose dogs with
TCC/PCA. The results of this study showed that
urine S100A8/A9 and the uCalR may have limited
diagnostic utility in dogs with TCC/PCA. Concentrations
of urine S100A8/A9 as well as the parameters of diagnos-
tic accuracy (AUROC, sensitivity, and specificity) and the
optimum cut-offs for the separation of dogs diagnosed
with TCC/PCA from the other groups of dogs were com-
parable to those in one study evaluating urine S100A8/A9
concentrations in humans with bladder cancer [30]. The
study by Ebbing et al. also showed higher urine concentra-
tions of S100A8/A9 in people with higher grade urothelial
carcinomas [30]. However, the possibility of a correlation
between urinary concentrations of the S100/calgranulins
and the results of complete cancer staging and/or grading,
response to treatment, and the individual patient outcome
were not investigated as part of our study, and this will
need to be further explored. Further research is also
needed to determine when changes in S100A8/A9 and
S100A12 could possibly occur along the spectrum of
tumor development and whether these tests can detect
pre-cancerous pathology or early cancer.
The components of diagnostic accuracy for the urinary
S100/calgranulins in this study were higher than the
sensitivity and specificity reported for urine sediment
analysis, where neoplastic cells are detectable in approxi-
mately 30% of patients with TCC but neoplastic cells can
be difficult to distinguish from reactive epithelial cells as-
sociated with inflammation [3, 5]. Also, both sensitivity
and specificity of the S100A8/A9USG were higher than
those of the V-BTA [6–9]. But similar to the V-BTA meas-
urement, the S100A8/A9USG in dogs ≥6 years of age also
suffers from a moderate rate of false positives (59% for
dogs with a UTI and 24% [18–33%] for the remaining
groups of dogs when using a cut-off of ≥109.9), which is
also consistent with the increased urinary proteome
fraction of S100A8/A9 and S100A12 (i.e., S100A8/A9Prot
and S100A12Prot) in TCC/PCA dogs with concurrent
UTI. An additional advantage over the V-BTA test [8],
S100A8/A9USG is not affected by hematuria and offers a
quantitative result [34].
The high sensitivity and NPV of S100A8/A9USG
observed in this study suggest that measuring S100A8/
A9USG could be a good screening test for TCC/PCA in
dogs, especially patients where a UTI has been ruled out
as a cause of clinical signs of lower urinary tract dis-
ease, and that a negative test result (i.e., a S100A8/
A9USG of <109.9) essentially excludes a diagnosis of
TCC/PCA in dogs. The uCalR, on the other hand, ap-
pears to be a better marker to distinguish patients with
a UTI from those with TCC/PCA. However, the false
negative rate of the uCalR in dogs ≥6 years old with a
UTI was still moderate (54% and 43% when using ≥5.2
and ≥9.1 as the cut-off concentration, respectively), but
a combination of S100A8/A9USG and the uCalR improved
the diagnostic accuracy (i.e., specificity) for the detection
of TCC/PCA in dogs. Similar to the V-BTA test [8], the
PPV of the uCalR and S100A8/A9USG increased to about
30% if used in a population of dogs with a higher index of
suspicion for lower urinary tract disease. Further pro-
spective studies are warranted in a larger cohort of dogs
to validate our findings and to directly compare the diag-
nostic performance of the urinary S100/calgranulins with
the V-BTA test.
Dog breeds reported to have a higher risk of developing
TCC (Scottish Terrier, West Highland White Terrier,
Shetland Sheepdog, Beagle, and Dachshund) [1–3, 36]
were overrepresented (36%) in our study. The female:male
ratio (1.4:1) as well as the urinary bladder trigone being
the most common tumor site were similar to previous re-
ports [1, 3, 4, 8]. Detection of a concurrent UTI in 42% of
the dogs with TCC/PCA (both treatment-naïve dogs and
dogs undergoing anticancer therapy) and the spectrum of
organisms isolated are also in line with the results of
others [37].
An interesting finding of the current study is that,
compared to dogs with TCC/PCA that received anticancer
treatment at the time of urine sample collection, treat-
ment-naïve dogs with TCC/PCA had 2.1- to 2.5-fold
higher urinary S100A8/A9 concentrations and 2.5- to
2.9-fold higher urinary S100A12 concentrations (albeit
statistical significance was reached only for S100A12Cre).
While the cause of urinary S100/calgranulins being lower
in dogs with TCC/PCA under treatment cannot be evalu-
ated through this study, potential explanations include a
decreased expression of these proteins by tumor cells or
reduction of tumor-associated inflammation (particularly
tumor-associated or even metastasis-associated macro-
phages) in response to treatment [38]. However, with the
source and treatment-induced change of S100A8/A9 and
S100A12 expression in canine TCC/PCA being unknown
and the relatively large variation in the uCalR seen in the
group of TCC/PCA dogs receiving anticancer treatment,
it remains to be determined whether the S100/calgranu-
lins are part of a pro-tumorigenic [39] or anti-tumorigenic
[40] signature in canine TCC/PCA [38], or if they may
even have a dual role. This distinction is particularly im-
portant as the synergism and convergence in the signaling
pathways of inflammation and cancer – especially the
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release of damage-associated molecular pattern molecules
(such as S100A8/A9 and S100A12), downstream activa-
tion of nuclear factor-κB, and expression of inflammatory
cytokines and chemokines – can lead to positive feedback
loops perpetuating chronic inflammation and thus a pro-
tumorigenic microenvironment [13, 38].
From a clinical perspective, these aspects lend them-
selves to research of novel molecular-based thera-
peutic strategies aimed at targeting tumor-associated
inflammation, which can drive tumor progression and
metastasis [38, 41]. From a comparative oncology
standpoint, study of the S100/calgranulins in canine
TCC/PCA is of very high interest because here the
spontaneous disease in dogs serves as a better model
for human urothelial carcinoma than murine models
(rodents lack S100A12 and S100A8 appears to func-
tionally resemble S100A12 [42–44]).
Another interesting finding in TCC/PCA dogs receiv-
ing anticancer therapy is that urinary S100A8/A9 and
S100A12 concentrations were lower with primary involve-
ment of the urinary bladder than that of the prostate.
Whether this reflects a higher degree of tumor-associated
inflammation with prostatic involvement, the response
(increased antitumor immunity or treatment-induced
inflammation) or even lack of response to treatment
[38] requires further study. In view of this finding, the
lack of a difference in urinary S100/calgranulin concentra-
tions between TCC/PCA dogs given an NSAID (either
alone or as part of a combination protocol) and those re-
ceiving other forms of antineoplastic therapy was unex-
pected as metronomic NSAIDs predominantly affect the
tumor-promoting inflammation [1, 38] and the expression
of S100A8 and S100A9 has been indirectly linked to the
cyclooxygenase (COX)-2/cAMP pathway [45, 46].
We acknowledge the limitation of the study that healthy
control dogs did not undergo the same diagnostic evalu-
ation as patients with TCC/PCA or other urinary tract or
non-urinary tract diseases. Thus, the possibility of an oc-
cult urinary tract disease (including TCC/PCA) cannot be
excluded with certainty in this group of dogs.
Conclusions
The results of this study show that urine S100A8/A9
and the uCalR have utility as an exclusionary tool in
dogs with suspected TCC/PCA. Despite a limited diagnos-
tic value (i.e., as a confirmatory test), the high sensitivity
and NPV of S100A8/A9USG suggests that S100A8/A9
could be a good screening test for TCC/PCA in dogs and
that the uCalR can help differentiate dogs with a UTI.
Further studies are warranted to validate our findings
in a larger cohort of dogs, to evaluate the source of
S100A8/A9 and S100A12 expression in canine TCC/PCA
patients, and to determine whether S100A8/A9 and/or
S100A12 expression correlates with tumor grade and/or
complete tumor stage, response to treatment, progression
of cancer, and/or survival time.
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